Katherine Moxley is an Oncology physician affiliated with Oklahoma Cancer Specialists and Research Institute. OpenAlex indexes 175 publications with 39,333 citations (h-index 55). By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
9 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
69.4%Iron, parenteral preparations69.4%Ferric carboxymaltose100%Part B, office-administered≥15 patientsMetabolism & gastrointestinal
24.2%Serotonin-3 Receptor Antagonist13.8%Granisetron99%Ondansetron Hcl1%Part D + Part B≥20 patientsSubstance P/Neurokinin-1 Receptor Antagonist10.4%Aprepitant100%Part B, office-administered≥12 patientsSensory organs
5.2%Corticosteroid5.2%Dexamethasone sodium phosphate100%Part B, office-administered≥41 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2020 per NIH RePORTER. The latest:
- Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma
University of Oklahoma Hlth Sciences Ctr
FY2020$216,227P20GM103639 - Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma
University of Oklahoma Hlth Sciences Ctr
FY2019$216,874P20GM103639 - Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma
University of Oklahoma Hlth Sciences Ctr
FY2018$217,500P20GM103639
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”